Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Seres Therapeutics, Inc. (MCRB)
|
Add to portfolio |
|
|
|
| Price: |
$21.00
| | Metrics |
| OS: |
128.2
|
M
| |
|
|
| Market cap: |
$2.69
|
B
| |
|
|
|
Net cash:
|
$129
|
M
| |
$1.00
|
per share
|
|
EV:
|
$2.56
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 7.1 | 143.9 | 11.9 | 27.2 | 28.3 | 32.1 | 21.8 | 0.0 |
| Revenue growth | -95.0% | 1109.2% | -56.2% | -3.8% | -11.9% | 47.5% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 7.1 | 143.9 | 11.9 | 27.2 | 28.3 | 32.1 | 21.8 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Selling, general and administrative | 253.6 | 209.4 | 121.3 | 106.4 | | | | |
| Research and development | | | | | 96.0 | 89.5 | 82.0 | 38.1 |
| General and administrative | | | | | 32.6 | 34.0 | 32.6 | 16.8 |
| EBIT | -253.8 | -66.7 | -90.1 | -68.7 | -100.3 | -91.4 | -92.8 | -54.9 |
| EBIT margin | -3560.9% | -46.3% | -757.5% | -252.6% | -354.8% | -284.7% | -426.5% | |
| Pre-tax income | -250.2 | -65.6 | -89.1 | -70.3 | -98.9 | -89.4 | -91.6 | -54.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -250.2 | -65.6 | -89.1 | -70.3 | -98.9 | -89.4 | -91.6 | -54.8 |
| Net margin | -3509.5% | -45.6% | -749.2% | -258.5% | -350.0% | -278.4% | -420.7% | |
| |
| Diluted EPS | ($2.31) | ($0.72) | ($1.12) | ($1.24) | ($2.43) | ($2.21) | ($2.30) | ($2.33) |
| Shares outstanding (diluted) | 108.1 | 91.7 | 79.8 | 56.6 | 40.7 | 40.4 | 39.8 | 23.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|